Shengtai Pharmaceutical, Inc. - Current report filing (8-K)
May 01 2008 - 7:57AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): April 30, 2008
SHENGTAI
PHARMACEUTICAL, INC.
(Exact
name of registrant as specified in charter)
Delaware
(State
or other jurisdiction
of
incorporation)
|
000-51312
(Commission
File Number)
|
54-2155579
(IRS
Employer
Identification
No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
PRC F4 262400
(Address
of principal executive offices)
|
Registrant’s
telephone number, including area code:
011-86-536-218-2777
____________________________________________
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b)
On
April
30, 2008, our Chief Financial Officer, Mr. Yizhao Zhang, resigned.
(c)
On
April
30, 2008, we appointed a new Chief Financial Officer, Ms. Yiru Shi. Ms. Shi
is
35 years old. Before April 30, 2008, Ms. Shi did not hold any position with
the
Company. Over the last five years, Ms. Shi has served as audit manager of Kabani
& Company Inc., where oversaw the audits and reviewed SEC filings for
numerous PRC companies that are also public companies in the U.S., and as
controller of Aroa Marketing.
There
are
no family relationship between Ms. Shi and any of our other officers and
directors. Ms. Shi is not a director of any Company. Except for the employment
agreement described below, Ms. Shi has not had any transaction with the Company
since the beginning of the Company’s last fiscal year.
(e)
Ms.
Shi’s
compensation as Chief Financial Officer of the Company is set forth in an
employment agreement between Ms. Shi and the Company. Under that agreement,
Ms.
Shi is to be employed by the Company for three years, and is to receive
compensation consisting of the following: (i) a salary of $108,000 per year;
(ii) options (or warrants) to purchase 50,000 shares of common stock of the
company at a strike price (or exercise price) of $3.30 per share each time
the
Company completes a financing transaction; (iii) if at the end of three years
she has not received stock options (or warrants) to purchase at least 150,000
shares of common stock of the Company, the difference between 150,000 and the
number of such options (or warrants) she has received; and (iv) in the
discretion of management, additional shares as a bonus.
Item
8.01 Other Events
On
May 1,
2008, we issued a press release disclosing our change in Chief Financial
Officer. The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
The
information in this report, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “
Exchange
Act
”),
or
incorporated subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended (the “
Securities
Act
”),
and
shall not be incorporated by reference in any registration statement or other
document filed under the Securities Act or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language
in
such filings, except as shall be expressly set forth by specific reference
in
such a filing.
Item
9.01
Financial
Statements and Exhibits
Exhibit
Index
Exhibit
99.1
Press
Release dated May 1, 2008
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Shengtai
Pharmaceutical, Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Yiru
Shi
|
|
Yiru
Shi
|
|
Duly
Authorized Signatory and
|
|
Chief
Financial Officer
|
|
|
Date: May
1, 2008
|
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Sep 2023 to Sep 2024